Compare ICICI Prudential Nifty Pharma Index Fund vs Tata India Pharma & Healthcare Fund
Risk | Very High | Very High |
Rating | 1.0 | 3.0 |
Min SIP Amount | ₹1000 | ₹100 |
Expense Ratio | 0.98 | 2.13 |
NAV | ₹16.35 | ₹28.89 |
Fund Started | 25 Nov 2022 | 04 Dec 2015 |
Fund Size | ₹94.36 Cr | ₹1310.50 Cr |
Exit Load | - | Exit load of 0.25% if redeemed within 30 days. |
Risk
Very High
Very High
Rating
1.0
3.0
Min SIP Amount
₹1000
₹100
Expense Ratio
0.98
2.13
NAV
₹16.35
₹28.89
Fund Started
25 Nov 2022
04 Dec 2015
Fund Size
₹94.36 Cr
₹1310.50 Cr
Exit Load
-
Exit load of 0.25% if redeemed within 30 days.
1 Year | -1.60% | -3.32% |
3 Year | 18.68% | 20.34% |
5 Year | - | 13.92% |
1 Year
-1.60%
-3.32%
3 Year
18.68%
20.34%
5 Year
-
13.92%
Equity | 99.95% | 98.68% |
Cash | 0.05% | 1.32% |
Equity
99.95%
98.68%
Cash
0.05%
1.32%
Top 10 Holdings |
|
|
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 22.05% |
Cipla Ltd. | 10.30% |
Divi's Laboratories Ltd. | 9.84% |
Dr. Reddy's Laboratories Ltd. | 9.38% |
Lupin Ltd. | 6.19% |
Laurus Labs Ltd. | 5.21% |
Torrent Pharmaceuticals Ltd. | 4.88% |
Aurobindo Pharma Ltd. | 4.01% |
Alkem Laboratories Ltd. | 3.90% |
Glenmark Pharmaceuticals Ltd. | 3.71% |
Sun Pharmaceutical Industries Ltd. | 7.88% |
Max Healthcare Institute Ltd. | 5.87% |
Abbott India Ltd. | 5.48% |
Divi's Laboratories Ltd. | 5.01% |
Healthcare Global Enterprises Ltd. | 4.84% |
Apollo Hospitals Enterprise Ltd. | 4.76% |
Cipla Ltd. | 4.14% |
Rainbow Children's Medicare Ltd. | 3.77% |
Ipca Laboratories Ltd. | 3.72% |
JB Chemicals & Pharmaceuticals Ltd. | 3.52% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index | The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India. |
Launch Date | 25 Nov 2022 | 04 Dec 2015 |
Description
The Scheme seeks to invest in companies whose securities are included in Nifty Pharma Index and subject to tracking errors, to endeavor to achieve the returns of the above index. This would be done by investing in all the stocks comprising the Nifty Pharma Index in the same weightage that they represent in Nifty Pharma Index
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Launch Date
25 Nov 2022
04 Dec 2015